RecruitingPhase 1NCT07270783
Healthy Volunteer Study
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of D-2570 Tablets in Healthy Subjects
Sponsor
InventisBio Co., Ltd
Enrollment
36 participants
Start Date
Dec 4, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria1
- Healthy volunteer subjects meeting eligibility criteria
Exclusion Criteria3
- Subjects with ongoing or history of disease or co-morbidities as assessed by Principal Investigator which would make them ineligible for the study
- Subjects with a history of drug and alcohol abuse
- Subjects taking medications, over the counter or herbal remedies
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGD-2570
D-2570
DRUGPlacebo
Placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07270783
Related Trials
Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study
NCT056524781 location
Characterization of Diseases With Salivary Gland Involvement
NCT023278841 location
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
NCT030653351 location
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT0705162910 locations
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
NCT062747491 location